219P Benchmarking state-of-the-art deep learning models for tumor-infiltrating lymphocytes (TILs) quantification
Masoud Tafavvoghi, Fakher Rahim, Sigve Andersen, Erna‐Elise Paulsen et autres
0 citationsESMO Real World Data and Digital Oncology
D.J. Pinato
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
12Publications signalées
24Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesMultiple and Secondary Primary CancersLiver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging
Publications récentes
206P Development of a machine-learning model on pre-treatment characteristics to predict long-term survivorship to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
Fakher Rahim, P-C. Lee, C. Yoo, Hong Jae Chon et autres
0 citationsESMO Real World Data and Digital Oncology
P1.11.62 Deep Learning Histopathology Model for PD-L1 (TPS) and Immunotherapy Outcome Prediction in Non-Small Cell Lung Cancer
Mehrdad Rakaee, Masoud Tafavvoghi, A. Cortellini, Sigve Andersen et autres
0 citationsJournal of Thoracic Oncology
3190eP Prognostic value of unplanned hospital attendances in early phase cancer trial participants
P. Lombardi, M. Filetti, A. Cortellini, R. Giusti et autres
0 citationsAnnals of Oncology
161P Real-world outcomes for unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab plus bevacizumab (A+B) in the United States (US)
D.J. Pinato, Natasha Shamas, Matthew H. Secrest, Anthony T. Tan et autres
0 citationsAnnals of Oncology
175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Hao Yang, Giulia Francesca Manfredi, Ciro Celsa et autres
1 citationAnnals of Oncology
178P Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Pasquale Lombardi, Erik Ramon‐Gil, Giulia Francesca Manfredi, Leonardo Brunetti et autres
0 citationsAnnals of Oncology
T.12.9 EARLY HEPATIC DECOMPENSATION IDENTIFIES PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB OR SORAFENIB AT HIGHEST RISK OF DEATH
C. Celsa, G. Cabibbo, S. Battaglia, M. Enea et autres
0 citationsDigestive and Liver Disease
Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib
G. Cabibbo, C. Celsa, S. Battaglia, M. Enea et autres
0 citationsDigestive and Liver Disease
969P Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
Pasquale Lombardi, Giulia Francesca Manfredi, Ciro Celsa, Bernardo Stefanini et autres
0 citationsAnnals of Oncology
The ALBI Grade Provides Objective Hepatic Reserve Phenotyping across Each BCLC Stage of Hepatocellular Carcinoma
D.J. Pinato, Ratnadeep Sharma, C. Yen, T. Arizumi et autres
3 citationsJournal of Hepatology
741 A NOVEL AND VALIDATED PROGNOSTIC INDEX IN HEPATOCELLULAR CARCINOMA: THE INFLAMMATION BASED INDEX (IBI)
D.J. Pinato, Justin Stebbing, M. Ishizuka, SALAH KHAN et autres
20 citationsJournal of Hepatology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.